HeadInvest LLC’s Ginkgo Bioworks DNA Stock Holding History

HeadInvest LLC’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5	Closed	-$374	–	340
2023 Q3	$374	Buy	+5	New	+$400	﹤0.01%	734

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HeadInvest LLC's DNA Position: Q4 2023 in Review

HeadInvest LLC sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 5 shares — an estimated $374 sold.

HeadInvest LLC first reported a position in DNA in Q3 2023 and held it in 1 quarter. The position peaked at $374 in Q3 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.

HeadInvest LLC reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
HeadInvest LLC sold 5 Ginkgo Bioworks shares in Q4 2023, an estimated $374.
HeadInvest LLC first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 1 quarter.
HeadInvest LLC's Ginkgo Bioworks position peaked at $374 in Q3 2023.
342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.